JP2015502740A - 炎症性腸疾患の診断を改善するための方法 - Google Patents

炎症性腸疾患の診断を改善するための方法 Download PDF

Info

Publication number
JP2015502740A
JP2015502740A JP2014537335A JP2014537335A JP2015502740A JP 2015502740 A JP2015502740 A JP 2015502740A JP 2014537335 A JP2014537335 A JP 2014537335A JP 2014537335 A JP2014537335 A JP 2014537335A JP 2015502740 A JP2015502740 A JP 2015502740A
Authority
JP
Japan
Prior art keywords
sample
ibd
antibody
markers
asca
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014537335A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015502740A5 (https=
Inventor
フレッド プリンセン，
フレッド プリンセン，
スティーブン ロックトン，
スティーブン ロックトン，
リサ， ジェイ． クローナー，
リサ， ジェイ． クローナー，
フレデリック， エー． フレッチャー，
フレデリック， エー． フレッチャー，
トーマス ストックフィッシュ，
トーマス ストックフィッシュ，
シャラット シング，
シャラット シング，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nestec SA
Original Assignee
Nestec SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestec SA filed Critical Nestec SA
Publication of JP2015502740A publication Critical patent/JP2015502740A/ja
Publication of JP2015502740A5 publication Critical patent/JP2015502740A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/40—Population genetics; Linkage disequilibrium
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/49—Platelet-derived growth factor [PDGF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70542—CD106
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Public Health (AREA)
  • Theoretical Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Primary Health Care (AREA)
  • Physiology (AREA)
JP2014537335A 2011-10-21 2012-10-19 炎症性腸疾患の診断を改善するための方法 Pending JP2015502740A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161550293P 2011-10-21 2011-10-21
US61/550,293 2011-10-21
US201161553853P 2011-10-31 2011-10-31
US61/553,853 2011-10-31
US201161567096P 2011-12-05 2011-12-05
US61/567,096 2011-12-05
US201161570271P 2011-12-13 2011-12-13
US61/570,271 2011-12-13
PCT/US2012/061202 WO2013059732A1 (en) 2011-10-21 2012-10-19 Methods for improving inflammatory bowel disease diagnosis

Publications (2)

Publication Number Publication Date
JP2015502740A true JP2015502740A (ja) 2015-01-29
JP2015502740A5 JP2015502740A5 (https=) 2015-12-10

Family

ID=48141435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014537335A Pending JP2015502740A (ja) 2011-10-21 2012-10-19 炎症性腸疾患の診断を改善するための方法

Country Status (9)

Country Link
US (2) US8715943B2 (https=)
EP (1) EP2769321B1 (https=)
JP (1) JP2015502740A (https=)
AU (1) AU2012325798B2 (https=)
CA (1) CA2852954A1 (https=)
IL (1) IL232167A0 (https=)
MX (1) MX352274B (https=)
SG (1) SG11201401536QA (https=)
WO (1) WO2013059732A1 (https=)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018513461A (ja) * 2015-03-03 2018-05-24 ナントミクス，エルエルシー アンサンブルに基づいたリサーチ・レコメンデーションシステムおよび方法
WO2018101470A1 (ja) * 2016-12-02 2018-06-07 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
JP2019516375A (ja) * 2016-05-20 2019-06-20 シーダーズ—シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
JP2019194600A (ja) * 2013-05-24 2019-11-07 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 過敏性腸症候群を診断するための経路特異的マーカー
US11101038B2 (en) 2015-01-20 2021-08-24 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer
JP2022097301A (ja) * 2020-12-18 2022-06-30 花王株式会社 ストレスマーカー及びそれを用いた慢性ストレスレベルの検出方法
JP2022097303A (ja) * 2020-12-18 2022-06-30 花王株式会社 疲労マーカー及びそれを用いた疲労の検出方法
JP2023517292A (ja) * 2020-03-06 2023-04-25 ラボラトリー コーポレイション オブ アメリカ ホールディングス ヘモグロビンａ（ｈｂａ）検出のためのアッセイおよび遺伝子型決定
JP2023093512A (ja) * 2016-02-02 2023-07-04 マキシマス ダイアグノスティック テクノロジーズ エルエルシー 炎症性腸疾患の処置を改善するための腸管バリア機能の評価

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
CA2758531C (en) 2009-04-14 2018-11-13 Derren Barken Inflammatory bowel disease prognostics
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
JP2014517279A (ja) 2011-05-10 2014-07-17 ネステク ソシエテ アノニム 個別治療管理のための疾患活動性プロファイリングの方法
KR102343212B1 (ko) 2013-03-27 2021-12-23 세다르스-신나이 메디칼 센터 Tl1a 기능 및 관련된 신호전달 경로의 저해에 의한 섬유증 및 염증의 완화 및 반전
WO2014182689A1 (en) * 2013-05-06 2014-11-13 Yacyshyn Bruce R Method of using biomarkers in predicting inflammatory bowel disease
WO2014186750A2 (en) 2013-05-17 2014-11-20 Cedars-Sinai Medical Center Variants of tnfsf15 and dcr3 associated with crohn's disease
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
US11568982B1 (en) 2014-02-17 2023-01-31 Health at Scale Corporation System to improve the logistics of clinical care by selectively matching patients to providers
EP3167392A4 (en) * 2014-07-11 2018-08-01 Matatu Inc. Use of a gut microbiome as a predictor of animal growth or health
CN104131102B (zh) * 2014-08-07 2016-06-15 马飞 一种判断nsclc患者对吉非替尼治疗反应性的试剂盒
US11809501B2 (en) 2014-08-28 2023-11-07 Ebay Inc. Systems, apparatuses, and methods for providing a ranking based recommendation
CA2969326A1 (en) * 2014-12-02 2016-06-09 Nestec S.A. Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease
US11037070B2 (en) * 2015-04-29 2021-06-15 Siemens Healthcare Gmbh Diagnostic test planning using machine learning techniques
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2
US11978543B2 (en) 2016-12-14 2024-05-07 Astarte Medical Partners Inc. System and methods for developing and using a microbiome-based action component
EP3554362A4 (en) * 2016-12-14 2020-08-12 Warren, Tracy SYSTEM AND METHODS FOR DEVELOPING AND USING A MICROBIOME-BASED ACTION COMPONENT FOR PATIENT HEALTH
US10409734B1 (en) * 2017-03-27 2019-09-10 Symantec Corporation Systems and methods for controlling auxiliary device access to computing devices based on device functionality descriptors
CN108784666B (zh) * 2017-05-04 2023-01-13 深圳市生码医疗科技有限公司 连续监测心血管的精准医疗系统及数据处理方法
AU2018277256A1 (en) 2017-05-31 2020-01-30 Prometheus Biosciences, Inc. Methods for assessing mucosal healing in Crohn's disease patients
CA3083792A1 (en) * 2017-12-18 2019-06-27 Personal Genome Diagnostics Inc. Machine learning system and method for somatic mutation discovery
WO2019195146A1 (en) 2018-04-03 2019-10-10 Boston Scientific Scimed, Inc. Systems and methods for diagnosing and/or monitoring disease
EP3818544B1 (en) 2018-07-05 2025-05-28 Boston Scientific Scimed, Inc. Devices, systems, and methods for determining inflammation and/or fibrosis
CA3108719A1 (en) * 2018-08-21 2020-02-27 Bruce R. Yacyshyn Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
WO2020112890A1 (en) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Rnaset2 compositions and methods of treatment therewith
CA3121167A1 (en) * 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Methods of stratifying and treating a sub-population of inflammatory bowel disease patients
WO2020117795A1 (en) * 2018-12-04 2020-06-11 Prometheus Biosciences, Inc. Assessment and monitoring of mucosal healing in children and adults with crohn's disease
CA3128973A1 (en) 2019-03-04 2020-09-10 Bhaskar Bhattacharyya Data compression and communication using machine learning
EP3958732A4 (en) * 2019-04-23 2023-01-18 Cedars-Sinai Medical Center METHODS AND SYSTEMS FOR ASSESSING INFLAMMATORY DISEASE WITH DEEP LEARNING
WO2020232262A1 (en) * 2019-05-16 2020-11-19 Procisedx Inc. Assay detection methods for vcam-1 and calprotectin
CN110373457B (zh) * 2019-06-20 2023-03-14 镇江市第一人民医院 一种用于溃疡性结肠炎诊断的mRNA标志物及其应用
CN111417124A (zh) * 2019-06-28 2020-07-14 西南交通大学 在认知无线网络环境下频谱感知的方法
US11610679B1 (en) * 2020-04-20 2023-03-21 Health at Scale Corporation Prediction and prevention of medical events using machine-learning algorithms
EP4162076A4 (en) * 2020-06-03 2024-10-02 Cedars-Sinai Medical Center TREATMENTS FOR A SUBPOPULATION OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE
US12094582B1 (en) 2020-08-11 2024-09-17 Health at Scale Corporation Intelligent healthcare data fabric system
US12080428B1 (en) 2020-09-10 2024-09-03 Health at Scale Corporation Machine intelligence-based prioritization of non-emergent procedures and visits
US20230363695A1 (en) * 2020-09-16 2023-11-16 Northwestern University Classification of functional lumen imaging probe data
WO2022076372A1 (en) * 2020-10-05 2022-04-14 Cedars-Sinai Medical Center Methods and systems for stratifying inflammatory bowel disease patients
CA3201128A1 (en) * 2020-12-04 2022-06-09 Manish Arora Systems and methods for dynamic immunohistochemistry profiling of biological disorders
WO2022125867A1 (en) * 2020-12-11 2022-06-16 Icahn School Of Medicine At Mount Sinai Methods of monitoring inflammatory bowel diseases
WO2022177963A1 (en) 2021-02-17 2022-08-25 Prometheus Biosciences, Inc. Anti-cd30l antibodies and uses thereof
US20240404053A1 (en) * 2021-09-22 2024-12-05 Janssen Research & Development, Llc Automatic Estimation of Ulcerative Colitis Severity from Endoscopy Videos USING ORDINAL MULTI-INSTANCE LEARNING
EP4469788A4 (en) * 2022-01-28 2025-12-24 Univ Southern California IDENTIFICATION OF NON-DISEALED PATIENTS USING DISEASE-ASSOCIATED ASSAY AND ANALYSIS IN LIQUID BIOPSY

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524008A (ja) * 2005-12-01 2009-06-25 プロメテウス ラボラトリーズ インコーポレイテッド 炎症性腸疾患を診断する方法
WO2010056682A2 (en) * 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4277250A (en) 1979-12-10 1981-07-07 Baylor College Of Medicine Methods for detecting and quantifying occult blood
JPH0684970B2 (ja) 1987-03-31 1994-10-26 株式会社京都医科学研究所 糞便中の潜血検出方法
US5081040A (en) 1987-06-29 1992-01-14 Helena Laboratories Corporation Composition and kit for testing for occult blood in human and animal excretions, fluids, or tissue matrixes
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
JPH0736013B2 (ja) 1991-04-27 1995-04-19 一男 田畑 潜血検出用試薬
US5885527A (en) 1992-05-21 1999-03-23 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membrances
EP0615129B1 (en) 1993-03-10 2000-05-31 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis or primary sclerosing cholangitis
US5830675A (en) 1993-03-10 1998-11-03 Cedars-Sinai Medical Center Methods for selectively detecting perinuclear anti-neutrophil cytoplasmic antibody of ulcerative colitis, primary sclerosing cholangitis, or type 1 autoimmune hepatitis
JP4285766B2 (ja) 1994-03-23 2009-06-24 オハイオ ユニバーシティ 緻密にした核酸および細胞へのデリバリ
US5972901A (en) 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
US5844107A (en) 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5932429A (en) 1996-04-12 1999-08-03 Cedars-Sinai Medical Center Methods of diagnosing clinical subtypes of crohn's disease
US6033864A (en) 1996-04-12 2000-03-07 The Regents Of The University Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using microbial UC pANCA antigens
US5916748A (en) 1996-04-12 1999-06-29 Cedars-Sinai Medical Center Method of diagnosing a clinical subtype of crohn's disease with features of ulcerative colitis
US6074835A (en) 1996-04-12 2000-06-13 Regents Of The Univ. Of California Diagnosis, prevention and treatment of ulcerative colitis, and clinical subtypes thereof, using histone H1
US5750479A (en) 1997-02-14 1998-05-12 Bandon Corp. Enclosed fluid system conditioner and process therefor
WO1998037415A1 (en) 1997-02-20 1998-08-27 The Regents Of The University Of California ULCERATIVE COLITIS pANCA SECRETORY VESICLE ANTIGEN AND METHODS OF USING SAME
US6218129B1 (en) 1998-05-15 2001-04-17 Prometheus Laboratories, Inc. Inflammatory bowel disease first step assay system
US6406862B1 (en) 1998-10-06 2002-06-18 The United States Of America As Represented By The Secretary Of The Army Dip-stick assay for C-reactive protein
US6309643B1 (en) 1999-04-30 2001-10-30 The Regents Of The University Of California IBD-associated microbial antigens and methods of using same
ATE340560T1 (de) 1999-05-24 2006-10-15 Introgen Therapeutics Inc Verfahren und zusammensetzungen für nichtvirale gentherapie zur behandlung von hyperproliferativen krankheiten
FR2802536B1 (fr) 1999-11-23 2003-06-13 Chru Lille Oligomannosides de synthese, leur preparation et leur utilisation a la detection d'anticorps et a la prevention d'infections
FR2806739B1 (fr) 2000-03-27 2005-02-18 Fond Jean Dausset Ceph Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation
US6838250B2 (en) 2000-03-31 2005-01-04 Ortho-Clinical Diagnostics, Inc. Immunoassay for C-reactive protein
US7138237B1 (en) 2000-05-19 2006-11-21 Cedars-Sinai Medical Center Diagnosis, prevention and treatment of Crohn's disease using the OmpC antigen
US20020042388A1 (en) 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
US6821739B2 (en) 2000-10-13 2004-11-23 The Regents Of The University Of California Methods of diagnosing and treating Crohn's disease using Pseudomonas antigens
WO2002032396A2 (en) 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
CA2427684C (en) 2000-10-30 2012-03-06 The Regents Of The University Of Michigan Nod2 nucleic acids and proteins
AU2002243415B2 (en) 2000-10-30 2007-05-24 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
US7060442B2 (en) 2000-10-30 2006-06-13 Regents Of The University Of Michigan Modulators on Nod2 signaling
US20050164929A1 (en) 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
AU2002220029B2 (en) 2000-11-14 2007-09-06 Techlab, Inc. Method for differentiating between irritable bowel syndrome and inflammatory bowel disease using lactoferrin as marker
JP2004535388A (ja) 2001-04-30 2004-11-25 ターゲティッド ジェネティクス コーポレイション 脂質含有薬物送達複合体およびそれらの生成方法
CA2860702C (en) 2001-12-17 2019-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
US20030204507A1 (en) 2002-04-25 2003-10-30 Li Jonathan Qiang Classification of rare events with high reliability
US20040053263A1 (en) 2002-08-30 2004-03-18 Abreu Maria T. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease
AU2003284187B2 (en) 2002-10-25 2009-10-01 Techlab, Inc. Inflammatory bowel disease and irritable bowel syndrome IBD-first chek diagnostic panel
WO2004048600A2 (en) 2002-11-22 2004-06-10 Emory University Diagnostic tests and methods for diagnosing inflammatory bowel disease
US7662569B2 (en) 2003-04-11 2010-02-16 Cedars-Sinai Medical Center Methods of assessing Crohn's disease patient phenotype by I2 serologic response
KR100731693B1 (ko) 2003-04-23 2007-06-25 에자이 알앤드디 매니지먼트 가부시키가이샤 질환 예후 모델의 작성 방법, 이 모델을 이용한 질환 예후예측 방법, 이 모델에 의한 예후 예측 장치, 및 그의프로그램ㆍ기억 매체
US20040242972A1 (en) 2003-05-28 2004-12-02 General Electric Company Method, system and computer product for prognosis of a medical disorder
US20050060295A1 (en) 2003-09-12 2005-03-17 Sensory Networks, Inc. Statistical classification of high-speed network data through content inspection
CA2549971A1 (en) 2003-11-03 2005-05-12 Duke University Methods of identifying individuals at risk of perioperative bleeding, renal dysfunction or stroke
EP1723432A1 (en) 2004-02-05 2006-11-22 Medtronic, Inc. Methods and apparatus for identifying patients at risk for life threatening arrhythmias
US7759079B2 (en) 2004-05-13 2010-07-20 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
WO2006012472A1 (en) 2004-07-21 2006-02-02 Qualyst, Inc. Apparatus, kits and methods for evaluating binding interactions, for detecting and quantifying binding molecules, and for sample preparation
US20100021455A1 (en) 2004-12-08 2010-01-28 Cedars-Sinai Medical Center Methods for diagnosis and treatment of crohn's disease
US7873479B2 (en) 2005-12-01 2011-01-18 Prometheus Laboratories Inc. Methods of diagnosing inflammatory bowel disease
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
US20100015156A1 (en) 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
US8153443B2 (en) 2007-05-10 2012-04-10 Cedars-Sinai Medical Center Characterization of the CBir1 antigenic response for diagnosis and treatment of Crohn's disease
US8557463B2 (en) 2008-03-27 2013-10-15 JX Nippon Oil Energy Corporation Fuel cell system and method for load following operation of the same
WO2010151699A1 (en) * 2009-06-25 2010-12-29 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
BR112012012513A2 (pt) * 2009-11-25 2017-01-10 Prometheus Lab Inc método para diagnosticar síndrome do intestino irritável em um paciente, método para monitorar a progressão ou regressão da síndrome do intestino irritável em um paciente, e para designar uma terapia contra síndrome do intestino irritável a um paciente em necessidade do mesmo
CA2801575A1 (en) 2010-06-04 2011-12-08 Prometheus Laboratories Inc. Methods for improving inflammatory bowel disease diagnosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009524008A (ja) * 2005-12-01 2009-06-25 プロメテウス ラボラトリーズ インコーポレイテッド 炎症性腸疾患を診断する方法
WO2010056682A2 (en) * 2008-11-11 2010-05-20 Prometheus Laboratories Inc. Methods for prediction of inflammatory bowel disease (ibd) using serologic markers
US20110045476A1 (en) * 2009-04-14 2011-02-24 Prometheus Laboratories Inc. Inflammatory bowel disease prognostics

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ADVANCES IN GENETICS, 2010年, vol. 72, JPN6016034663, pages 73 - 99, ISSN: 0003395234 *
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010年, vol. Vol.25, Suppl.3, JPN6016034667, pages 80 - 84, ISSN: 0003395236 *
THE AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010年, vol. Vol.105, Issue S1, JPN6016034666, pages 471 - 1279, ISSN: 0003395233 *
WORLD JOURNAL OF GASTROENTEROLOGY, 2007年, vol. 13, no. 14, JPN6016034665, pages 2028 - 2036, ISSN: 0003395235 *

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019194600A (ja) * 2013-05-24 2019-11-07 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 過敏性腸症候群を診断するための経路特異的マーカー
US11101038B2 (en) 2015-01-20 2021-08-24 Nantomics, Llc Systems and methods for response prediction to chemotherapy in high grade bladder cancer
JP2018173969A (ja) * 2015-03-03 2018-11-08 ナントミクス，エルエルシー アンサンブルに基づいたリサーチ・レコメンデーションシステムおよび方法
JP2018513461A (ja) * 2015-03-03 2018-05-24 ナントミクス，エルエルシー アンサンブルに基づいたリサーチ・レコメンデーションシステムおよび方法
JP2023093512A (ja) * 2016-02-02 2023-07-04 マキシマス ダイアグノスティック テクノロジーズ エルエルシー 炎症性腸疾患の処置を改善するための腸管バリア機能の評価
US12379385B2 (en) 2016-02-02 2025-08-05 Maximus Diagnostic Technologies Llc Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function
JP2019516375A (ja) * 2016-05-20 2019-06-20 シーダーズ—シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
US12545959B2 (en) 2016-05-20 2026-02-10 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
JP7475811B2 (ja) 2016-05-20 2024-04-30 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
KR20220025122A (ko) * 2016-05-20 2022-03-03 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
JP2022095688A (ja) * 2016-05-20 2022-06-28 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
JP2024037945A (ja) * 2016-05-20 2024-03-19 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
JP7392020B2 (ja) 2016-05-20 2023-12-05 シーダーズ―シナイ メディカル センター 遺伝子に基づく炎症性腸疾患の診断
KR102481305B1 (ko) 2016-05-20 2022-12-26 세다르스-신나이 메디칼 센터 유전자에 기반한 염증성 장 질환의 진단
US11549146B2 (en) 2016-05-20 2023-01-10 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease based on genes
JP7111322B2 (ja) 2016-12-02 2022-08-02 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
US11866497B2 (en) 2016-12-02 2024-01-09 The University Of Tokyo Antibody to fibrosis-related molecule and medical application thereof
US11117962B2 (en) 2016-12-02 2021-09-14 The University Of Tokyo Antibody to fibrosis-related molecule and medical application thereof
JP2018090524A (ja) * 2016-12-02 2018-06-14 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
WO2018101470A1 (ja) * 2016-12-02 2018-06-07 国立大学法人 東京大学 線維化関連分子に対する抗体およびその医療応用
JP2023517292A (ja) * 2020-03-06 2023-04-25 ラボラトリー コーポレイション オブ アメリカ ホールディングス ヘモグロビンａ（ｈｂａ）検出のためのアッセイおよび遺伝子型決定
JP2022097303A (ja) * 2020-12-18 2022-06-30 花王株式会社 疲労マーカー及びそれを用いた疲労の検出方法
JP2022097301A (ja) * 2020-12-18 2022-06-30 花王株式会社 ストレスマーカー及びそれを用いた慢性ストレスレベルの検出方法
JP7655720B2 (ja) 2020-12-18 2025-04-02 花王株式会社 ストレスマーカー及びそれを用いた慢性ストレスレベルの検出方法
JP7655721B2 (ja) 2020-12-18 2025-04-02 花王株式会社 疲労マーカー及びそれを用いた疲労の検出方法

Also Published As

Publication number Publication date
IL232167A0 (en) 2014-06-30
US8715943B2 (en) 2014-05-06
AU2012325798B2 (en) 2015-11-26
WO2013059732A1 (en) 2013-04-25
US20150072879A1 (en) 2015-03-12
EP2769321A4 (en) 2015-05-13
AU2012325798A1 (en) 2013-05-16
MX352274B (es) 2017-11-16
EP2769321A1 (en) 2014-08-27
US20130225439A1 (en) 2013-08-29
EP2769321B1 (en) 2016-06-01
CA2852954A1 (en) 2013-04-25
HK1200933A1 (zh) 2015-08-14
SG11201401536QA (en) 2014-05-29
MX2014004712A (es) 2014-11-14

Similar Documents

Publication Publication Date Title
US8715943B2 (en) Methods for improving inflammatory bowel disease diagnosis
US9732385B2 (en) Method for determining the risk of crohn's disease-related complications
US20130203053A1 (en) Methods for improving inflammatory bowel disease diagnosis
US20120171672A1 (en) Inflammatory bowel disease prognostics
JP5634023B2 (ja) 試料が炎症性腸疾患と関連しているか分類する方法
JP5571951B2 (ja) 試料が過敏性腸症候群と関連するか否かを決定する分類方法
JP5749652B2 (ja) 血清学的マーカーを用いた炎症性腸疾患（ｉｂｄ）の予測方法
US20130005596A1 (en) Novel genomic biomarkers for irritable bowel syndrome diagnosis
US20120208212A1 (en) Methods of assessing crohn's disease patient phenotype by i2, ompc and asca serologic response
US7873479B2 (en) Methods of diagnosing inflammatory bowel disease
EP2710383B1 (en) Performance of a biomarker panel for irritable bowel syndrome
JP2018504584A (ja) 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法
EP2565277A1 (en) Method for predicting radiographic severity in ankylosing spondylitis
WO2011060098A1 (en) Methods for predicting post-surgery risk associated with ileal pouch-anal anastomosis
HK1200933B (en) Methods for improving inflammatory bowel disease diagnosis
WO2004091372A2 (en) Methods of assessing crohn’s disease patient phenotype by i2, ompc and asca serologic response

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160906

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170627